FDA approves Regeneron’s Libtayo for high-risk CSCC post-surgery
The US Food and Drug Administration (FDA) has granted approval to Regeneron Pharmaceuticals’ fully human monoclonal antibody Libtayo(cemiplimab-rwlc) as an adjuvant…
The US Food and Drug Administration (FDA) has granted approval to Regeneron Pharmaceuticals’ fully human monoclonal antibody Libtayo(cemiplimab-rwlc) as an adjuvant…
Trogenix has raised £70m ($95m) in Series A financing to help bring its “Trojan horse” cancer treatment into clinical trials,…
Genmab has signed an agreement to buy all shares of clinical-stage biotechnology company Merus at $97 per share, in an…
Sanofi has committed an additional $625m to its venture capital arm, Sanofi Ventures, bringing its total assets under management to…
The European Commission (EC) has sanctioned the use of Servier’s Voranigo (vorasidenib) to treat certain brain tumours, specifically non-enhancing grade…
GSK has announced an investment of $30bn in the US over the next five years for research and development (R&D)…
Eli Lilly is seeking a label expansion for earlier use of Jaypirca (pirtobrutinib) in treatment-naïve patients with chronic lymphocytic leukaemia…
Health Canada has approved AbbVie's antibody-drug conjugate (ADC), Elahere (mirvetuximab soravtansine for injection), to treat adults with certain types of…
China's National Medical Products Administration (NMPA) has granted conditional approval to Boehringer Ingelheim's Hernexeos (zongertinib tablets), for use as a…
Amphastar Pharmaceuticals has signed an exclusive licence agreement with Nanjing Anji Biotechnology, focusing on the development, production, use and commercialisation…